专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

US20160326524A1 RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES 审中-公开
标题翻译：基于RAAV的组合物和治疗ALPHA-1抗血小板缺乏症的方法
公开(公告)号：US20160326524A1
公开(公告)日：2016-11-10
申请号：US15098833
申请日：2016-04-14
申请人： University of Massachusetts
发明人： Terence Flotte , Christian Mueller
IPC分类号： C12N15/113 , A61K31/713 , A61K48/00 , A61K38/57 , C12N7/00 , C07K14/81
CPC分类号： C12N15/86 , A61K31/713 , A61K35/12 , A61K38/57 , A61K48/005 , A61K48/0058 , C07K14/8125 , C12N7/00 , C12N15/111 , C12N15/113 , C12N15/67 , C12N2310/141 , C12N2310/3519 , C12N2320/31 , C12N2750/14121 , C12N2750/14132 , C12N2750/14143
摘要： The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).
摘要翻译：本发明涉及分离的核酸和基于rAAV的组合物，用于治疗遗传疾病（例如α-1抗胰蛋白酶缺乏症）的方法和试剂盒。

72. 发明授权

US09457070B2 Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease 有权
标题翻译： α1-抗胰蛋白酶组合物，方法和用途，用于早期干预骨髓移植和治疗移植物抗宿主病
公开(公告)号：US09457070B2
公开(公告)日：2016-10-04
申请号：US13209349
申请日：2011-08-12
申请人： Charles A. Dinarello , Eli C. Lewis
发明人： Charles A. Dinarello , Eli C. Lewis
IPC分类号： A61K38/57 , A61K31/60 , A61K38/12 , A61K38/17 , C12Q1/37 , C07K7/64
CPC分类号： A61K38/57 , A01N1/021 , A61K31/60 , A61K35/28 , A61K38/12 , A61K38/179 , A61K39/3955 , A61K45/06 , A61K2035/124 , C07K16/24 , C12N5/0652 , C12N2501/734 , C12Q1/37 , G01N2333/81 , G01N2333/96433 , G01N2800/245
摘要： Embodiments of the present invention relate to compositions and methods for treatment of subjects in need of or having a bone marrow transplant. Certain embodiments describe compositions and methods for treatment of conditions associated with bone marrow transplantations in a subject, for example, Graft versus Host Disease (GvHD) or bone marrow transplantation rejection. Some embodiments concern early or immediate bone marrow transplantation rejection. Certain embodiments relate to compositions and uses of alpha1-antitrypsin (α1-antitrypsin, AAT) and carboxyterminal peptide derivatives thereof and/or compositions and uses of serine protease inhibitors, immunomodulators or anti-inflammatory agent activity similar to that of AAT.
摘要翻译：本发明的实施方案涉及用于治疗需要或具有骨髓移植的受试者的组合物和方法。某些实施方案描述了用于治疗与受试者的骨髓移植相关的病症的组合物和方法，例如，移植物抗宿主病（GvHD）或骨髓移植排斥反应。一些实施方案涉及早期或即刻骨髓移植排斥。某些实施方案涉及α1-抗胰蛋白酶（α1-抗胰蛋白酶，AAT）及其羧基端肽衍生物和/或丝氨酸蛋白酶抑制剂，免疫调节剂或类似于AAT的抗炎剂活性的组合物和用途的组合物和用途。

73. 发明申请

US20160279195A1 FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES 审中-公开
标题翻译：因子十二号药物管理与医疗程序包含与人工表面接触
公开(公告)号：US20160279195A1
公开(公告)日：2016-09-29
申请号：US15141036
申请日：2016-04-28
申请人： CSL Behring GmbH
发明人： Stefan ZEITLER , Marc NOLTE , Stefan SCHULTE , Gerhard DICKNEITE , Ingo PRAGST
IPC分类号： A61K38/17 , A61K38/58 , A61K31/727 , A61L33/12 , A61K39/395 , A61K47/48 , A61K38/57 , A61L33/00 , C07K16/40
CPC分类号： A61K38/1767 , A61K31/727 , A61K38/16 , A61K38/556 , A61K38/57 , A61K38/58 , A61K39/3955 , A61K47/643 , A61K47/65 , A61L33/0041 , A61L33/0082 , A61L33/128 , A61L2300/252 , A61L2300/256 , A61L2300/42 , A61L2420/00 , C07K16/36 , C07K16/40 , C07K2317/76
摘要： An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
摘要翻译： FXII / FXIIa的抑制剂，用于在对人或动物受试者进行的医疗过程期间和/或之后防止血栓的形成和/或稳定化，包括使人或动物受试者的血液与人造表面接触，其中所述抑制剂 FXII / FXIIa在所述医疗程序之前和/或期间和/或之后施用。

74. 发明授权

US09452203B2 Use of C1-inhibitor for the treatment of secondary edema of the central nervous system 有权
标题翻译：使用C1抑制剂治疗中枢神经系统的继发性水肿
公开(公告)号：US09452203B2
公开(公告)日：2016-09-27
申请号：US14364097
申请日：2012-12-21
申请人： CSL BEHRING GMBH
发明人： Christoph Kleinschnitz , Marc Nolte , Guido Stoll , Gerhard Dickneite , Stefan Schulte , Bernhard Nieswandt , Ingo Pragst
IPC分类号： A61K38/17 , A61K38/57
CPC分类号： A61K38/57
摘要： The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.
摘要翻译：在最一般的方面，本发明的主题是预防和/或治疗二次水肿。特别地，本发明涉及一种用于防止在受试者中具有或已经具有中枢神经系统（CNS）的中枢神经系统（CNS）的继发性水肿的形成和/或减小的方法的方法的C1抑制剂选自中风，缺血性中风，出血性中风，围产期中风，创伤性脑损伤和脊髓损伤的至少一种障碍。优选CNS的继发性水肿是继发性脑水肿。本发明的另一主题是治疗与血脑屏障或血液脊髓屏障的渗透性增加相关的病症。并且第三个受试者是用于预防，减少或治疗脑缺血 - 再灌注损伤的方法中的等离子体衍生的C1抑制剂。

75. 发明授权

US09415094B2 Method of reducing side effects associated with administration of tissue plasminogen activator (tPA) 有权
标题翻译：降低与组织纤溶酶原激活物（tPA）的给药相关的副作用的方法
公开(公告)号：US09415094B2
公开(公告)日：2016-08-16
申请号：US13349905
申请日：2012-01-13
申请人： Olivier Meilhac
发明人： Olivier Meilhac
IPC分类号： A61K38/57 , A61K9/127
CPC分类号： A61K38/57 , A61K9/1275 , G01N2800/2871
摘要： Provided is an HDL comprising an agent selected from the group consisting of antiproteases, antioxidants, antimitotics, anti-apoptotic agents and agents involved in the iron metabolism for use in methods of reducing side effects associated with administration of tissue plasminogen activator (tPA) in subjects in need of treatment.
摘要翻译：提供了一种HDL，其包含选自抗蛋白酶，抗氧化剂，抗虚证药，抗凋亡剂和参与铁代谢的试剂的试剂，用于减少受试者中组织纤溶酶原激活剂（tPA）施用相关的副作用的方法需要治疗。

76. 发明授权

US09352016B2 Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces 有权
标题翻译：用于用医学程序给药的因子XII抑制剂，包括与人造表面接触
公开(公告)号：US09352016B2
公开(公告)日：2016-05-31
申请号：US14004066
申请日：2012-03-09
申请人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
发明人： Stefan Zeitler , Marc Nolte , Stefan Schulte , Gerhard Dickneite , Ingo Pragst
IPC分类号： A61K9/00 , A61K36/00 , A61K38/16 , A61K38/55 , A61K38/57 , C07K16/36 , C07K16/40 , A61K31/727 , A61K38/17 , A61K47/48
CPC分类号： A61K38/1767 , A61K31/727 , A61K38/16 , A61K38/556 , A61K38/57 , A61K38/58 , A61K39/3955 , A61K47/643 , A61K47/65 , A61L33/0041 , A61L33/0082 , A61L33/128 , A61L2300/252 , A61L2300/256 , A61L2300/42 , A61L2420/00 , C07K16/36 , C07K16/40 , C07K2317/76
摘要： An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
摘要翻译： FXII / FXIIa的抑制剂，用于在对人或动物受试者进行的医疗过程期间和/或之后防止血栓的形成和/或稳定化，包括使人或动物受试者的血液与人造表面接触，其中所述抑制剂 FXII / FXIIa在所述医疗程序之前和/或期间和/或之后施用。

77. 发明申请

US20160129115A1 FORMULATIONS OF LIQUID STABLE ANTITHROMBIN 审中-公开
标题翻译：液体稳定抗凝血药的配方
公开(公告)号：US20160129115A1
公开(公告)日：2016-05-12
申请号：US14745276
申请日：2015-06-19
申请人： LFB USA, Inc.
发明人： Gerald R. Magneson , Greg J. Allard , Nicholas C. Masiello , Usha S. Patel , Lauren K. Fontana , Joseph L. Pearce , Jerry A. Grandoni
IPC分类号： A61K47/26 , A61K47/12 , A61K47/02 , A61K38/57
CPC分类号： A61K47/26 , A61K9/0019 , A61K38/4833 , A61K38/57 , A61K47/02 , A61K47/12
摘要： In one aspect, the invention provides liquid stable formulations of antithrombin.
摘要翻译：一方面，本发明提供了抗凝血酶的液体稳定制剂。

78. 发明授权

US09320783B2 Methods of treatment using alpha-1-antitrypsin compositions 有权
标题翻译：使用α-1-抗胰蛋白酶组合物的治疗方法
公开(公告)号：US09320783B2
公开(公告)日：2016-04-26
申请号：US14802885
申请日：2015-07-17
申请人： CSL Behring L.L.C.
发明人： Scott M. Kee , Paul I. Cook , James R. Smith , Robert Kling , Scott A. Fowler , David Weber
IPC分类号： A61K38/57 , B01D15/32 , B01D15/36 , C07K14/81 , G01N30/46
CPC分类号： A61K38/57 , A61K9/19 , B01D15/327 , B01D15/363 , C07K14/8125 , G01N30/461
摘要： A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.
摘要翻译：提供了从含有AAT的蛋白质混合物（例如Coh级分IV沉淀）中纯化α-1-抗胰蛋白酶（AAT）的流线型方法。在本发明的方法中，通过用不影响AAT的还原剂如二硫醇裂解二硫键，污染蛋白质不稳定。然后将不稳定的蛋白质优先吸附在固体蛋白质吸附材料上，而不添加盐作为沉淀物。固体吸收剂与溶液的分离留下直接适用于色谱纯化的纯化的AAT溶液，而不需像现有技术方法一样进行广泛的脱盐。还描述了一种以商业规模提供高产量的药物级AAT的方法。

79. 发明申请

US20160095931A1 COMPOSITIONS CONTAINING HC-HA COMPLEX AND METHODS OF USE THEREOF 审中-公开
标题翻译：包含HC-HA复合物的组合物及其使用方法
公开(公告)号：US20160095931A1
公开(公告)日：2016-04-07
申请号：US14869609
申请日：2015-09-29
申请人： TissueTech, Inc.
发明人： Scheffer TSENG , Hua HE
IPC分类号： A61K47/48 , A61K38/57
CPC分类号： A61K38/57 , A61K38/00 , A61K47/55 , A61K47/61 , C07K14/78 , Y02A50/414
摘要： Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof.
摘要翻译：在某些实施方案中，本文公开了包含透明质酸和IαI重链的HC·HA复合物，其中IαI重链的转移被TSG-6催化。本文进一步公开，在某些实施方案中，是包含透明质酸和IαI重链的HC·HA复合物，其中IαI重链的转移由TSG-6样蛋白催化。此外，本文公开了制备所述复合物的方法及其使用方法。

80. 发明申请

US20160008442A1 TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY 审中-公开
标题翻译：治疗和预防远期间隔再灌注损伤
公开(公告)号：US20160008442A1
公开(公告)日：2016-01-14
申请号：US14773020
申请日：2014-03-07
申请人： CSL BEHRING GMBH , UNIVERSITÄT BERN
发明人： Rolf SPIRIG , Sylvia MIESCHER , Marc NOLTE , Claudia DUEHRKOP-SISEWITSCH , Robert RIEBEN
IPC分类号： A61K38/57
CPC分类号： A61K38/57 , A61K45/06
摘要： The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitor to an individual.
摘要翻译：本发明涉及用于治疗和/或预防远端缺血再灌注损伤（IRI）的接触激活系统抑制剂，优选C1INH，其包括将接触激活系统抑制剂施用给个体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式